

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of Financial status**  
**as of 31 of March 2019**

	31.03.2019	31.12.2018
	BGN'000	BGN'000
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	24 757	25 754
Intangible assets	3 452	2 871
Investment in minority interest	1	1
Trade receivables	4 968	4 968
<b>Total non-current assets</b>	<b>33 178</b>	<b>33 594</b>
<b>Current assets</b>		
Inventories	6 179	5 491
Trade and other receivables	73 432	71 608
Current corporate income tax	-	92
Treasury shares redeemed	4	4
Cash and cash equivalents	350	250
<b>Total current assets</b>	<b>79 965</b>	<b>77 445</b>
<b>Total assets</b>	<b>113 143</b>	<b>111 039</b>
<b>LIABILITIES</b>		
<b>Equity</b>		
Share capital	72 200	72 200
Reserves	10 601	10 601
Retained earnings	14 352	11 199
<b>Total</b>	<b>97 153</b>	<b>94 000</b>
<b>Non-current liabilities</b>		
Long-term loans	148	180
Deferred tax liabilities	1 264	1 264
Retirement benefit obligations	119	119
<b>Total non-current liabilities</b>	<b>1 531</b>	<b>1 563</b>
<b>Current liabilities</b>		
Trade and other liabilities	4 022	4 186
Short-term loans	9 786	9 785
Current portion of long-term loans	329	409
Current corporate income tax		217
Other tax liabilities	322	879
<b>Total current liabilities</b>	<b>14 459</b>	<b>15 476</b>
<b>Total liabilities</b>	<b>15 990</b>	<b>17 039</b>
<b>Total equity and liabilities</b>	<b>113 143</b>	<b>111 039</b>

Date of preparation: 23.04.2019

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/



**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of comprehensive income**  
**as of 31 of March 2019**

	<b>31.03.2019</b>	<b>31.03.2018</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenue	9 332	9 164
Other income		
<b>Total income</b>	<b>9 332</b>	<b>9 164</b>
Carrying amount of goods sold	(35)	(534)
Changes in inventories of finished products and work in progress	454	124
Materials and services	(4 057)	(3 585)
Personnel expenses	(990)	(870)
Depreciation / amortisation expenses	(944)	(879)
Other expenses	(335)	(82)
Finance income	2	5
Finance costs	(90)	(74)
<b>Total expenses</b>	<b>(5 995)</b>	<b>(5 895)</b>
<b>Profit before taxation</b>	<b>3 337</b>	<b>3 269</b>
Corporate income tax expense	(184)	(246)
<b>Profit/Loss for the period</b>	<b>3 153</b>	<b>3 023</b>
 <b>Total comprehensive income for the period</b>		
Earnings per share / in BGN per 1 share /	0.04	0.05

Date of preparation: 23.04.2019

Sofia

Prepared by:.....  
 / P. Moneva /

Executive Director:.....  
 /B. Georgiev/



**Tchaikapharma High Quality Medicines Inc.**  
**Interim cash flow statement**  
**as of 31 of March 2019**

	31.03.2019	31.03.2018
	<i>BGN'000</i>	<i>BGN'000</i>
<b>Cash flows from operating activities</b>		
Proceeds from sale of finished products, goods and services	8 521	6 463
Payments to suppliers of materials, goods and services	(4 191)	(2 906)
Payments to personnel	(880)	(795)
Payments of interest and dividends	(9)	(2)
Corporate income tax payments	(309)	(325)
Other proceeds / payments	(2 504)	(1 654)
<b>Net cash flows</b>	<b>628</b>	<b>781</b>
<b>Cash flows from investing activities</b>		
Payments on non-current assets acquired	(350)	(588)
<b>Net cash flows</b>	<b>(350)</b>	<b>(588)</b>
<b>Cash flows from financial activities</b>		
Proceeds from loans	50	
Payments on loans	(49)	
Payment of interest, dividends	(61)	(49)
Payments on finance lease	(118)	(137)
Other proceeds/payments		(3)
<b>Net cash flows</b>	<b>(178)</b>	<b>(189)</b>
<b>Change in cash and cash equivalents</b>		
Cash and cash equivalents at the beginning of the period	250	24
Cash and cash equivalents at the end of the period	350	28

Date of preparation: 23.04.2019


Sofia

Prepared by:.....

/ P. Moneva /

Executive  
Director:.....

/B. Georgiev /



**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement on changes in equity**  
**as of 31 of March 2019**

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
<b>Balance as of 01.01.2018</b>	<b>63 400</b>	<b>3 626</b>	<b>5 546</b>	<b>8 831</b>	<b>82 303</b>
Profit/loss for the period				11 199	11 199
Other comprehensive income		498			498
Including from tax effect of the revaluation of property, plant and equipment		(72)			(72)
<b>Total comprehensive income</b>		<b>498</b>		<b>11 199</b>	<b>11 697</b>
Issue of shares by the owners	7 900			(7 900)	
Dividends accrued					
Tantimmes accrued					
Profit transferred to reserves			931	(931)	
<b>Total amount of income and expenses recognised during the period</b>	<b>7 900</b>		<b>931</b>	<b>(8 831)</b>	
<b>Balance as of 31.12.2018</b>	<b>72 200</b>	<b>4 124</b>	<b>6 477</b>	<b>11 199</b>	<b>94 000</b>
<b>Balance as of 01.01.2019</b>	<b>72 200</b>	<b>4 124</b>	<b>6 477</b>	<b>11 199</b>	<b>94 000</b>
Profit/loss for the period				3 153	3 153
Other comprehensive income					
<b>Total comprehensive income</b>				<b>3 153</b>	<b>3 153</b>
Issue of shares by the owners					
Dividends accrued					
Tantimmes accrued					
Profit transferred to reserves					
<b>Total amount of income and expenses recognised during the period</b>					
<b>Balance as of 31.03.2019</b>	<b>72 200</b>	<b>4 124</b>	<b>6 477</b>	<b>14 352</b>	<b>97 153</b>

Date of preparation: 23.04.2019  
Sofia

Prepared by:.....  
/P. Moneva/

Executive Director:.....  
/B. Georgiev /

